Three Liquid Biopsy Panels Target Myeloid Genes, EGFR Pathways, and TP53

Scientist hand holding test tube with blood in laboratory.
Scientist hand holding test tube with blood in laboratory.

Fluxion Biosciences has launched three new targeted NGS liquid biopsy panels: Spotlight Myeloid, Spotlight EGFR, and Spotlight TP53. The new panels complement the company’s Spotlight 59 pan-cancer panel, and have been validated with Fluxion’s ERASE-Seq variant caller.

Spotlight Myeloid is a 478-amplicon panel covering 23 clinically-relevant genes implicated in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (NPM). Because of the high prevalence of myeloid variants in clonal hematopoiesis of indeterminate potential (CHIP) studies, the panel can uncover CHIP variants in either cell-derived or cfDNA samples.

The Spotlight EGFR Pathway Panel has contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS, using a 17-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. The Spotlight TP53 Panel contains 21 amplicons with an average size of 140bp, providing comprehensive coverage of all TP53 coding regions.

Each panel comes with the variant caller ERASE-Seq, Fluxion’s statistically powered variant caller, which delivers detection sensitivity to 0.1% allele frequency, with a false positive rate 10-100X lower than molecular barcode (UMI) approaches.

The new panels include primers and indexed sequencing adapters for Illumina sequencers.

This site uses Akismet to reduce spam. Learn how your comment data is processed.